<unk> , sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder. While it was being studied for generalized anxiety disorder, such research had stopped as of 2017. It is taken by mouth. Common side effects include nausea, diarrhea, and trouble sleeping. Serious side effects may include increased suicidal thoughts or actions in those under the age of 25, serotonin syndrome, bleeding, mania, pancreatitis, and SIADH.<unk>  may cause less emotional blunting than typical SSRIs and SNRIs. A withdrawal syndrome may occur if the dose is rapidly decreased. Use during pregnancy and breastfeeding is not generally recommended. It is in the serotonin modulator class of medications and is believed to work both as an SSRI and activator of the 5-HT1A receptor.<unk>  was approved for medical use in the United States in 2011 and in Canada in 2018. In 2017, it was the 285th most commonly prescribed medication in the United States, with more than one million prescriptions. The drug loses patent protection in June 2022 for adults, and exclusivity for pediatrics in July 2023. Several generic versions have been approved by the FDA, but are not yet on the market as of April 2022.
Vilazodone
Hydrocodone
Nefazodone
Trazodone
Tapentadol
Naltrexone
Tramadol
Norhydrocodone